RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo takes aim at High-Risk leukemia
Disease control OngoingThis phase 2 pilot study is testing whether combining two drugs, ibrutinib and daratumumab, can improve outcomes for people with relapsed or refractory chronic lymphocytic leukemia (CLL) that has a p53 gene problem. The 29 participants will take ibrutinib daily and receive daratu…
Matched conditions: RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Italian study tracks how venetoclax works for CLL patients in everyday practice
Knowledge-focused OngoingThis observational study follows 321 Italian patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax-based regimens outside of clinical trials. The goal is to describe their clinical features and outcomes, such as how long they live…
Matched conditions: RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC